

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SINO BIOPHARMACEUTICAL LIMITED
中國生物製藥有限公司

(Incorporated in the Cayman Islands with limited liability)

Website: www.sinobiopharm.com

(Stock code: 1177)

VOLUNTARY ANNOUNCEMENT
APPLICATION FOR MARKETING OF “LOXOPROFEN SODIUM CATAPLASMS”
FILED AND ACCEPTED

The board of directors (the “**Board**”) of Sino Biopharmaceutical Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that an application for marketing of “Loxoprofen Sodium Cataplasms” developed by the Group has been filed with and accepted by the National Medical Products Administration of the People’s Republic of China. The product is used for anti-inflammation and analgesia of the diseases and symptoms such as osteoarthritis, muscle pain, and swelling and pain due to injuries. For external use, it is applied to the affected area once a day and one patch at a time.

Loxoprofen sodium is a non-steroidal anti-inflammatory drug (NSAID) in the phenylpropionic acid group. Its mechanism of action is to reduce the synthesis of prostaglandin from arachidonic acid by inhibiting cyclooxygenase so as to achieve anti-inflammatory, antipyretic and analgesic effects. It can be widely applied with quick effect, especially strong analgesic effect. Compared with other NSAIDs, loxoprofen sodium is a prodrug, which has no significant irritating effect on the gastrointestinal tract and is well tolerated. Leveraging on the Group’s modern technology platform of topical cataplasms, the Loxoprofen Sodium Cataplasms developed by the Group has shown remarkable efficacy, high safety and good skin compatibility in clinical trials. With strong comfort level at the application location but no tearing pain, odor or skin patch marks, it significantly improves patient compliance.

As another key cataplasm product of the Group after Flurbiprofen Cataplasms and Lidocaine Cataplasms, Loxoprofen Sodium Cataplasms further strengthens the Group's product pipeline in analgesic drugs for injuries. This product is expected to be the second loxoprofen sodium cataplasm available in China, breaking the monopoly of the domestic loxoprofen sodium cataplasm market and providing more treatment options for patients.

By order of the Board
Sino Biopharmaceutical Limited
Tse, Theresa Y Y
Chairwoman

Hong Kong, 30 June 2023

As at the date of this announcement, the Board of the Company comprises seven executive directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y, Mr. Tse Hsin, Mr. Tian Zhoushan and Ms. Li Mingqin and five independent non-executive directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong, Mr. Zhang Lu Fu and Dr. Li Kwok Tung Donald.